Biomarin Pharmaceutical (NASDAQ:BMRN) received mixed analyst ratings over the past three months, with a recent average price target of $106.00, down from $117.71. Analysts from firms including Baird, Stifel, RBC Capital, BMO Capital, Piper Sandler, Morgan Stanley, Barclays, and Cantor Fitzgerald have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. BioMarin focuses on rare-disease therapies and has seen a revenue growth rate of 15.04% as of September 30, 2023. The company's market capitalization is below the industry average, but it has a strong net margin of 6.95%, an exceptional ROE of 0.83%, and an impressive ROA of 0.61%, with a conservative debt-to-equity ratio of 0.22.